IQVIA (NYSE:IQV) Shares Gap Down – Time to Sell?

IQVIA Holdings Inc. (NYSE:IQV) gapped down prior to trading on Thursday . The stock had previously closed at $177.18, but opened at $162.93. IQVIA shares last traded at $166.4330, with a volume of 1,267,486 shares.

Analyst Ratings Changes

Several research analysts have recently weighed in on IQV shares. Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Mizuho set a $266.00 price objective on shares of IQVIA in a report on Friday, January 9th. Morgan Stanley set a $240.00 target price on shares of IQVIA in a report on Wednesday. Finally, Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $238.20.

IQVIA Stock Performance

The company has a market capitalization of $28.56 billion, a P/E ratio of 21.32, a PEG ratio of 1.76 and a beta of 1.37. The stock’s fifty day moving average price is $225.42 and its 200-day moving average price is $209.47. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.70 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm had revenue of $4.36 billion for the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the previous year, the business earned $3.12 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Several hedge funds have recently bought and sold shares of the stock. Claret Asset Management Corp lifted its holdings in IQVIA by 1.1% during the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the last quarter. Versant Capital Management Inc boosted its position in shares of IQVIA by 6.3% in the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after acquiring an additional 53 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. boosted its position in shares of IQVIA by 3.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the period. Brookstone Capital Management grew its stake in shares of IQVIA by 2.2% in the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after acquiring an additional 63 shares in the last quarter. Finally, Private Advisor Group LLC raised its stake in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.